CAR T-cell therapy for relapsed neurological autoimmune diseases
Treatments studied
Part of Brain & nervous system, Cancer, Eyes & vision, Immune system & allergy clinical trials.
This early-stage trial tests a new type of immune cell therapy (CAR T-cells) against several relapsed or hard-to-treat autoimmune diseases that affect the nervous system. The goal is to see if this treatment can safely calm the immune system and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have a specific neurological autoimmune disease that has relapsed or not responded to treatment (like NMOSD, myasthenia gravis, multiple sclerosis, autoimmune encephalitis, or CIDP).
- If you could become pregnant or father a child, you must use birth control during treatment and for 6 months after.
- You cannot have severe drug allergies, recent cancer (except some low-risk types), certain infections (like hepatitis B, C, HIV, or syphilis), or heart problems.
- Pregnant or breastfeeding women cannot join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a universal CAR-T cell treatment for people with autoimmune diseases of the nervous system that haven't responded to standard therapies. It aims to see if this therapy can help control diseases like neuromyelitis optica, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multiple sclerosis.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This trial tests a new treatment called MB-CART2019.1, which uses your own immune cells to fight multiple sclerosis. It is for people with progressive or worsening MS who have not responded well to other treatments.
This trial tests a treatment called CNCT19, a type of CAR-T cell therapy, for people with certain autoimmune diseases like neuromyelitis optica, myasthenia gravis, or multiple sclerosis that have come back or not responded to other treatments. It aims to see if targeting a specific immune cell (CD19) can help control the disease.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.